Ahead of its FY22 results, Arovella has released its quarterly activities report, reiterating key developments and milestones achieved in the closing quarter of the financial year. While the key highlight was the signing of the manufacturing agreement with Q-Gen for its chimeric antigen receptor-invariant natural killer T (CAR-iNKT) programme ALA-101, initiation of commercial activities (with the launch of ZolpiMist in Australia) was another major milestone. Arovella also secured the US patent f ....
01 Aug 2022
Arovella Therapeutics - Recap of a busy quarter
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Arovella Therapeutics - Recap of a busy quarter
Arovella Therapeutics Limited (ALA:ASX) | 0 0 6.7% | Mkt Cap: 19.5m
- Published:
01 Aug 2022 -
Author:
Soo Romanoff -
Pages:
2
Ahead of its FY22 results, Arovella has released its quarterly activities report, reiterating key developments and milestones achieved in the closing quarter of the financial year. While the key highlight was the signing of the manufacturing agreement with Q-Gen for its chimeric antigen receptor-invariant natural killer T (CAR-iNKT) programme ALA-101, initiation of commercial activities (with the launch of ZolpiMist in Australia) was another major milestone. Arovella also secured the US patent f ....